Home / Recalls / Imprimis NJOF, LLC / D-0250-2026

D-0250-2026 Class II Ongoing

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

Recall Details

Product Type
Drugs
Report Date
January 14, 2026
Initiation Date
December 18, 2025
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
596 boxes of 11,920 pre-filled syringes

Product Description

Dexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, NDC 71384-513-01.

Reason for Recall

Presence of particulate matter - Glass like particles.

Distribution Pattern

U.S Nationwide

Code Information

Lot: 25APR001A, 25APR001B, Expires: 04/03/2026.

Other recalls by Imprimis NJOF, LLC

  • D-0251-2026 Class II — Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use In (December 18, 2025)
  • D-0249-2026 Class II — Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, R (December 18, 2025)
  • D-0157-2026 Class III — Klarity-C Drops (Cyclosporine) 0.1%, Preservative-Free Sterile Ophthalmic Emulsi (October 20, 2025)
  • D-0535-2025 Class II — Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx (July 9, 2025)
  • D-0536-2025 Class III — Tropicamide-Proparacaine-Phenylephrine-Ketorolac, Sterile Ophthalmic Solution, 1 (July 9, 2025)
  • D-0305-2025 Class III — Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthalmic Soluti (February 24, 2025)
  • D-0519-2024 Class II — Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single- (May 14, 2024)
  • D-0513-2024 Class II — Dexamethasone-Moxifloxacin (1 mg/mL and 5mg/mL) Preservative-Free, 1mL Single-Us (May 14, 2024)
  • D-0512-2024 Class II — Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single- (May 14, 2024)
  • D-0516-2024 Class II — Moxifloxacin 4 mg/0.8 mL Preservative-Free 0.8mL Single-Use vials for Intraocula (May 14, 2024)